#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Semaglutide cut fentanyl seeking in rats
A 2026 rat study found that single doses of semaglutide prevented cue-, drug- and stress-triggered fentanyl seeking. Human trials are next.
Semaglutide and Alzheimer's: EVOKE review
A new paper revisits the EVOKE trials and finds limited semaglutide signals at later timepoints, despite the primary endpoint failure at two years.
Semaglutide weight loss: the trial data
STEP 5 shows 15% average weight loss sustained at two years. What the data says about body composition, eating behaviour, and stopping.
Semaglutide resolves MASLD inflammation
A 2026 meta-analysis of 10 trials found semaglutide resolved steatohepatitis and cut liver fat in MASLD patients, but fibrosis improvement was not significant.
Semaglutide and menstrual changes
Semaglutide users report heavier periods and cycle shifts. Here is what safety data and clinical research say about GLP-1 agonists and menstruation.
Semaglutide eased RLS in Parkinson's case
A 2026 case report found that semaglutide improved treatment-resistant restless legs syndrome in one Parkinson's disease patient. The finding is preliminary.
Semaglutide below max dose: real-world data
A Slovak observational study found 11.35% mean weight loss at six months on submaximal semaglutide doses. Below trial figures, but clinically relevant.
Most statin label warnings lack evidence
A 2026 Lancet meta-analysis found only 4 of 66 listed statin side effects are backed by trial evidence. What GLP-1 users should know.
Greener route to tirzepatide synthesis
A 2026 JACS study combines tag-assisted synthesis with selenoester ligation to assemble peptide drugs up to 39 residues long using far less solvent.
GLP-1 drugs in teens: what youth say
A qualitative study of 29 adolescents on GLP-1 and other weight-loss drugs finds families are positive about treatment but uncertain about when to stop.
GLP-1 drugs and severe GI motility risk
A 626,000-person cohort study found GLP-1 therapies carry a 37% higher relative risk of severe GI events versus SGLT-2 inhibitors.
Tirzepatide after bariatric surgery
An Italian study reports 18.1% weight loss at 24 weeks in 34 post-bariatric patients on tirzepatide. Early data, small sample.